Akums Drugs and Pharmaceuticals Limited (AKUMS) breaks out, gaining +5% today backed by its Q1 FY27 results showing a 13.9% YoY revenue increase. The stock cleared its 6-month resistance trendline, signaling a bullish breakout. Akums, a mid-cap drug manufacturer specializing in generics, saw its stock move align with strong quarterly performance rather than broader sector momentum.

Technical setup — trendlines & DMA

The current trendline structure shows a 6-month support floor at ₹724, just 1.6% below today’s price, and resistance at ₹728, which the stock has now broken above by 1.1%. The 50-DMA at ₹630.3 is above the 200-DMA at ₹511.6, indicating a positive trend. AKUMS is currently 11% above the 50-DMA, suggesting some extension. Within its 52-week range of ₹409.3 to ₹714.7, the stock is in the upper third, implying that a significant portion of its move is already priced in.

Fundamentals & business context

With a PE of 42.1 and profit margins at 5.9%, AKUMS’s valuation appears stretched relative to its current earnings, especially given its moderate revenue CAGR of 7.0%. However, the strong profit CAGR of 39.1% over 5 years suggests potential for margin expansion. Institutional ownership stands at 13.3%, indicating a cautiously optimistic view from smart money. There is no new NSE catalyst today beyond the Q1 results.

Algorithmic scorecard

The overall score reflects a technically strong but fundamentally mixed profile. Two of the strongest signals are the bullish trend, with the 50-day average above the 200-day average, and the bullish sentiment over the last 30 days, where up days saw nearly double the volume of down days. These indicate systematic accumulation and positive market sentiment. On the weaker side, the low profit margin of 5.9% leaves little room for error, and the negligible dividend yield of 0.15% offers little income for investors, highlighting potential risks.

Company outlook

Management provided forward guidance indicating expected double-digit volume growth in the CDMO business for H1 FY27. The trade generics business is expected to remain stable, while the API business is projected to see reduced losses. The Zambia project is set to commence commercial supplies of $25 million by the end of Q2 FY27, and a European CDMO contract is expected to contribute EUR35 million on a MAT basis starting from the next fiscal. Plans include additional plants getting European GMP approved over the next 18 months, investments in capacity expansion, R&D, and modernization, and expansion of the oral solid facility due to increased volume growth.

Get all details on AKUMS — P&L, peers, shareholding and more on TradeAlone.

Akums Drugs and Pharmaceuticals Limited (AKUMS) announced its consolidated financial results for the quarter ended June 30, 2026, marking a strong start to FY27. The company delivered healthy growth in revenue, operating profitability and PAT, supported by continued momentum in its CDMO business, improved operating performance and healthy customer demand.

Revenue Surge

Akums reported operating revenue of ₹1,167 crore in Q1 FY27, registering a 13.9% year-on-year growth compared with ₹1,024 crore in Q1 FY26. This robust performance was primarily driven by the CDMO business, which saw a significant increase in revenue and EBITDA.

EBITDA and PAT Growth

EBITDA increased 35.4% year-on-year to ₹175 crore, with EBITDA margin improving to 15.0% from 12.6%. PAT stood at ₹101 crore, compared with ₹65 crore in the corresponding quarter last year. PAT margin also improved to 8.4% from 6.2%.

CDMO Business Performance remained the key growth driver during the quarter. CDMO revenue increased to ₹964 crore, compared with ₹813 crore in Q1 FY26, while CDMO EBITDA grew 36.8% year-on-year to ₹163 crore from ₹119 crore in Q1 FY26, supported by continued volume growth and improvement in API prices.

Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, ‘FY27 has begun on a strong and encouraging note. The consistent performance of CDMO showcases healthy demand environment as well as our clients’ trust in Akums as the preferred manufacturing partner.’ Mr. Sandeep Jain, Managing Director, added, ‘We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable growth in the years ahead.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Akums gains 25.2% over three months and trades near its 52-week highs. Thin margins at 5.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 7.0%, profits at 39.1%, and the PEG sits at 1.08 — below its growth rate. That combination is rare. Check Fundamentals of Akums Drugs and Pharmaceuticals Limited.

Akums Drugs and Pharmaceuticals Limited (AKUMS) breaks out, gaining +5% to ₹692.85 on the NSE on 10 Jul 2026. The stock cleared its 6-month resistance trendline, marking a significant technical move. This breakout comes amid a backdrop of strong sector performance, with AKUMS now positioned in the upper third of its 52-week range. The move aligns with the company’s solid revenue growth and strategic initiatives, though it is somewhat company-specific given the recent trendline clearance.

Technical setup — trendlines & DMA

From a technical standpoint, AKUMS has broken above its 6-month resistance trendline, which ended at ₹646.53, now sitting 6.69% above this level. The 6-month support trendline is at ₹608.77, with the current price 12.14% above this floor. The stock is trading 15% above its 50-day moving average (DMA) of ₹570.6, indicating an extended move. The 50-DMA is above the 200-DMA of ₹488.4, signaling a bullish trend. AKUMS is currently in the upper third of its 52-week range, suggesting that a substantial portion of the move is already priced in, though the breakout indicates continued upward momentum.

Fundamentals & business context

Fundamentally, AKUMS presents a mixed picture. With a PE of 39.6 and profit margins at 5.9%, the valuation appears stretched relative to current earnings, especially given the revenue CAGR of 7.0%. However, the profit CAGR of 39.1% over the past five years suggests that the market may be pricing in a turnaround or future growth. Institutional ownership stands at 13.2%, indicating a cautious but present interest from smart money. There is no specific NSE catalyst today, but the overall technical breakout and strong sector performance contribute to the positive sentiment.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weaker position for AKUMS. The strongest signals include the bullish trend, with the 50-DMA above the 200-DMA, and the breakout above resistance levels with momentum, indicating a robust upward move. Additionally, the stock’s consistent revenue growth every year underscores exceptional business stability. On the weaker side, the low profit margin of 5.9% leaves little room for error, and the negligible dividend yield of 0.15% offers little income for investors. These factors highlight the need for cautious optimism despite the strong technical performance.

Company outlook

Management’s outlook for AKUMS is optimistic, with expected double-digit volume growth in the CDMO segment for H1 FY27. The trade generics business is anticipated to maintain similar revenue and EBITDA levels, while the API business is projected to see reduced losses in FY27. The Zambia project is set to commence commercial supplies of $25 million by the end of Q2 FY27, and the European CDMO contract is expected to contribute EUR35 million on a MAT basis starting from the next fiscal. Additionally, plans include obtaining European GMP approval for additional plants within the next 18 months, investments in capacity expansion, R&D, and modernization, and the expansion of the oral solid facility due to increased volume growth.

Get all details on AKUMS — P&L, peers, shareholding and more on TradeAlone.